Follow us on Twitter
twitter icon@FreshPatents


Autologous patents

      

This page is updated frequently with new Autologous-related patent applications.




 Systems and methods for repairing soft tissues patent thumbnailSystems and methods for repairing soft tissues
A wicking component is integrated into an arthroscopically deployable bone anchor, and is intended to improve soft tissue-to-bone repair. Once deployed, the fibrous wick component extends from within the bone tunnel, out of the hole, and to the bone-tendon interface on the bone surface.
Cayenne Medical, Inc.


 Multilineage stem cells derived from the peripheral blood and uses thereof patent thumbnailMultilineage stem cells derived from the peripheral blood and uses thereof
The present invention discloses recovery and isolation of mesenchymal stem cells from the peripheral blood. This has an advantage of being able to obtain multilineage inducible cells from readily obtainable and autologous allogenic blood.
Vivex Biomedical, Inc.


 Tissue grafts and methods of making and using the same patent thumbnailTissue grafts and methods of making and using the same
In some embodiments, the present invention provides tissue grafts, such as vascularized bone grafts, and methods for preparing and using such tissue grafts. In some embodiments the tissue grafts are made using pluripotent stem cells, such as autologous pluripotent stem cells.
The New York Stem Cell Foundation


 Polyhydroxyalkanoate medical textiles and fibers patent thumbnailPolyhydroxyalkanoate medical textiles and fibers
Absorbable polyester fibers, braids, and surgical meshes with prolonged strength retention have been developed. These devices are preferably derived from biocompatible copolymers or homopolymers of 4-hydroxybutyrate.
Tepha, Inc.


 Method for obtaining immuno-stimulatory dendritic cells patent thumbnailMethod for obtaining immuno-stimulatory dendritic cells
The present invention relates to methods for producing immuno-stimulatory autologous dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from hyper-proliferative disease such as cancer..
Yale University


 Muscle tissue regeneration using muscle fiber fragments patent thumbnailMuscle tissue regeneration using muscle fiber fragments
The invention is directed to methods and compositions for obtaining uniform sized muscle fiber fragments for transplantation. These muscle fiber fragments are able to reconstitute into long fibers that are oriented along native muscle.
Wake Forest University Health Sciences


 Composition and methods of genome editing of b-cells patent thumbnailComposition and methods of genome editing of b-cells
The present invention provides methods compositions and methods of preparing autologous (or allogeneic) b cells that secrete a monoclonal of interest useful in immunotherapy or b cells with an altered function.. .
Dana-farber Cancer Institute, Inc.


 Surgical methods/devices for tissue injury removal by tattooing of autologous stem cells patent thumbnailSurgical methods/devices for tissue injury removal by tattooing of autologous stem cells
A method and a device for autografting of fat microparticles containing stem cells of various types, injected into scars, or stretch marks, and/or other cutaneous injuries, at epidermis-dermis level is presented. Fat is taken from the patient in the periumbilical area, where large quantities of mesenchymal stem cells exist.

 Anti-wt1/hla bi-specific antibody patent thumbnailAnti-wt1/hla bi-specific antibody
Disclosed herein is a bi-specific form of a t cell receptor mimic (tcrm) mab with reactivity to human immune effector cell antigen and a wt1 peptide/hla-a epitope. This antibody selectively bound to leukemias and solid tumor cells expressing wt1 and hla-a as well as activated resting human t cells to release interferon-(ifn-γ) and to kill the target cancer cells in vitro.
Eureka Therapeutics, Inc.


 Method of treating a pathological syndrome and a pharmaceutical agent patent thumbnailMethod of treating a pathological syndrome and a pharmaceutical agent
Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too..

Systems, compositions, and methods for transplantation and treating conditions

Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (a2m) from whole blood and or recombinant a2m are provided. Also provided are methods of treating wounds with a2m.
Cytonics Corporation

Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration

A method for diagnosing or treating a mammalian subject having, or at risk of developing cancer, comprising: generating a circulating anti-cancer cd4+ th1 response from antigen presenting cells or their precursors and cd4+ t-cells from a sample of said subject's blood which causes secretion of interferon-gamma (“ifn-γ”); and detecting said anti-cancer cd4+ th1 response to determine if said response is depressed. A method for restoring her2-specific cd4+ th1 immune response in a her2-positive breast cancer patient in need thereof, comprising: administering to said patient a therapeutically effective amount of a dendritic cell (“dc”) vaccine comprising autologous dcs pulsed with her2-derived mhc class ii binding peptides (“dc vaccination”) to elevate said patient's anti-her2 cd4+ th1 response; and measuring said anti-her2 th1 response of said patient pre- and post-dc vaccination to determine the amount of increase in said response..

Semi-allogenic anti-tumour vaccine with hla haplo-identical antigen-presenting cells

The present invention relates to semi-allogeneic antigen-presenting cells into which proteins and/or peptides or rna or dna or cdna, respectively, encoding said proteins and/or peptides which are overexpressed in tumor cells or which are derived from autologous tumor cells or different tumor cells or different tumor cell lines have been introduced. Furthermore the invention relates to methods for the generation of these semi-allogeneic antigen-presenting cells as well as to the use thereof in the treatment of tumor diseases..
Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (gmbh)

Biomarkers for cell therapy

The invention relates to methods for monitoring progression of an inflammatory condition in a subject in particular embodiments the patient is undergoing treatment of the inflammatory condition and the method comprises monitoring the level of one or more biomarkers to monitor disease progression, for example to assist the clinician in optimising the treatment regimen. In particular embodiments the subject is undergoing treatment with mesenchymal stem cells (mscs).
Cell Ideas Pty Ltd

Tissue processing device and associated systems and methods

Tissue processing devices are provided. The tissue processing devices can be used to process and transport tissue in a closed and continuous environment.
Lifecell Corporation

Probiotic enhancement of steroid and immune suppressor activity in mammals with chronic diseases

This invention relates to use of probiotics, particularly p acidilactici and s boulardii, for use in conjunction with steroids and other immune suppressor agents to ameliorate symptoms of autoimmune diseases, especially disease symptoms arising from the body's production of antibodies against autologous blood cells. The practice of the invention sustains ameliorative response associated with immune suppressor agents while lowering the amount of immune suppressor agents required for treatment..
Imagilin Technology, Llc

Compositions and methods for restoring or rejuvenating stem/progenitor cell function

This invention relates to the use of autologous stem/progenitor cells to restore or rejuvenate adult stem cell function in a mammal, wherein the restoration or rejuvenating extends lifespan and/or improves health of the mammal. In addition, the invention also relates to compositions containing one or more regulatory factors secreted or released from isolated mammalian stem/progenitor cells and use of such compositions to extend lifespan and/or improve health of a mammal.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Methods and compositions for ex vivo generation of developmentally competent eggs from germ line cells using autologous cell systems

The present technology provides for methods for the directed differentiation of multi-potent cells, female germ line stem cells, or oogonial stem cells into oocytes, granulosa cells and/or granulosa precursor cells, i.e.,“synthetic granulosa cells.” the synthetic granulosa cells are useful in methods for growth and maturation of follicles or follicle-like structures and immature oocytes. Additionally, the synthetic granulosa cells are useful in methods of increasing ovarian derived hormones and growth factors in a subject in need thereof..
Northeastern University

Formulation, apparatus, and methods for treatment of brain trauma

A formulation comprising platelet rich plasma (prp) for treatment of patients who have experienced brain injury, consisting of a mixture of human autologous plasma, d5w, glutathione, methylcobalamin, and regular insulin. The formulation is infused directly adjacent to a patient's brain through the nostrils or nares of the nasal cavity.

Device and surgical system for rapid aseptic isolation and concentration of autologous fat derived stem cells

The present disclosure provides an apparatus for harvesting stem cells from fat tissue. The apparatus may include a first transducer coupled to a first end of an resonant horn to form an ultrasonic resonator.

Self-contained device and system to produce ex-vivo autologous whole cell tumor vaccines

The invention disclosed herein aims to standardize and simplify the process of preparing ex-vivo autologous whole tumor cell vaccines. The present invention is a robust, stand-alone device and system for preparing autologous tumor cell vaccines in a completely self-contained sterile environment, and in a shortened time.

Bone tissue engineering by ex vivo stem cells ongrowth into three-dimensional trabecular metal

Adult autologous stem cells cultured on a porous, three-dimensional tissue scaffold-implant for bone regeneration by the use of a hyaluronan and/or dexamethasone to accelerate bone healing alone or in combination with recombinant growth factors or transfected osteogenic genes. The scaffold-implant may be machined into a custom-shaped three-dimensional cell culture system for support of cell growth, reservoir for peptides, recombinant growth factors, cytokines and antineoplastic drugs in the presence of a hyaluronan and/or dexamethasone alone or in combination with growth factors or transfected osteogenic genes, to be assembled ex vivo in a tissue incubator for implantation into bone tissue..

Clinical applications of formulations containing adipose-derived stem cells

Methods and kits for producing cellular fractions enriched in adipose derived stem cells. Methods are provided where adipose tissue obtained from liposuction is enzymatically treated using a solution containing collagenase and divalent cations prior to the application of traditional methods of stromal-vascular fraction isolation.
Antria, Inc.

Autologous cancer cell vaccine

An autologous cancer cell vaccine comprises cancer cells that express both mhci and mhcii on their cell surface. The mhci presents a cancer antigen and the mhcii presents a non-self antigen..

Method of preparing autologous cells and methods of use for therapy

A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium which can be used in a clinical setting, and a business method for performing such expansions in the future as a service for patients. A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium including a diagnostic kit for the autologous cell therapy to determine whether a patient will respond to the autologous cell therapy for treatment of a disease, in which said kit comprising a system for detecting gene and protein expression comprising at least two isolated dna molecules wherein each isolated dna molecule detects expression of a gene that is differentially expressed in the tissue of the patient that is intended to be the source of the autologous cell therapy..
Biocardia, Inc.

Induction of cellular senescence for tissue therapies

Provided are compositions and methods for aiding in healing of a tissue wound in an individual. The method generally entail delivering to an individual in need thereof senescent cells such that healing of the wound is accelerated.
Health Research, Inc.

Method of repairing age and disease immune dysfunction and cellular senescence with lymphoid stem cells and then re-applying those for therapeutic use

This invention relates to methods for treatment of diseases of ageing including immunosenescence, immune dysfunction, inflammation and impairment of early lymphoid lineage differentiation. The invention more specifically relates to the use of granulocyte colony stimulating factors to assist in stem cell mobilization, optionally in combination with the application of a method of delivering precise magnetic field patterns which agree with the body's own natural magnetic field patterns, and further in combination with re-infusion of previously collected autologous cells and/or plasma, optionally including allogeneic (healthy donor) cells and blood plasma..
Advanced Neuroregenerative Therapies, Llc

Autologous hiv-1 proteins for the treatment of latent hiv-1 infection

A method of reducing a latent hiv-specific memory-cd4+ t cell pool in a subject includes the steps of: preparing at least one hiv-1 protein coding sequence from a sample obtained from the subject, wherein the sample includes hiv-1 rna; introducing the at least one hiv-1 protein coding sequence into at least one expression construct using yeast homologous recombination; transfecting a cell with the at least one expression construct, wherein the hiv-1 protein is secreted by the cell and administering a therapeutically effective amount of the secreted hiv-1 protein and a pharmaceutically acceptable carrier to the subject, wherein the secreted hiv-1 protein stimulates latent hiv-specific memory-cd4+ t cells to induce latent hiv-1 replication resulting in hiv-specific memory-cd4+ t cell death in the subject.. .
Case Western Reserve University

Methods for the repair and rejuvenation of tissues using platelet-rich plasma compositions

This application relates to cosmetic methods for improving skin conditions. The methods generally include the administration of platelet-rich plasma and cultured autologous cells to a subject after a micro-needling procedure has been performed.

Method for analysis of nkt cell function

The present invention provides a superior method of functional analysis of nkt cells, which enables function analysis of low frequency nkt cells, is independent of the function of autologous apcs, and can avoid an influence of secondary factors and the like. More specifically, the present invention provides a method of functional analysis of human nkt cells including (a) cocultivating a mononuclear cell derived from human peripheral blood with a cd1d-expressing antigen presenting cell derived from a heterologous animal, and (b) evaluating the functionality of nkt cells with the number of nkt cells and/or a substance specific to functional nkt cells as an index; a reagent for analysis of human nkt cells containing a cd1d-expressing antigen presenting cell derived from a heterologous animal; a kit containing (a) a cd1d-expressing antigen presenting cell derived from a heterologous animal, and (b) at least one reagent selected from the group consisting of a reagent for selection of human mononuclear cell, a reagent for measurement of the number of human nkt cells and a reagent for measurement of a substance specific to human functional nkt cells; and the like..
Riken

Neocartilage constructs using universal cells

The invention relates to implantable systems for repairing and restoring cartilage. The invention provides methods and products for cartilage repair that use universal chondrocytes.
Histogenics Corporation

A flap for de-novo tissue regeneration

The present invention provides an implant which includes: (a) an autologous engineered tissue; and (b) a vasculature, wherein the engineered tissue is a porous scaffold embedded with endothelial cell, a fibroblast, a myoblast, a mesenchymal cell, an adipocyte, or any combination thereof, wherein the vasculature feeds the cells. Further, the invention provides a method for treating a subject afflicted with a large soft tissue defect by implanting the implant of the invention..
Health Corporation-rambam

Method of treating disorders of the cardiovascular system and a pharmaceutical agent

Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too..

Method of treating a pathological syndrome and a pharmaceutical agent

Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too..

Apparatus for blood concentration

A disposable blood transfer conduit is used in association with a pump drive unit, a blood collection vessel and a blood concentration device. The blood transfer conduit comprises a blood transfer tube (13) and a peristaltic pump element (12) having an enclosed housing mounted about the blood transfer tube (12).
Brightwake Limited

Regulatory b cells (tbregs) and their use

Regulatory b cells (tbreg) are disclosed herein. These regulatory b cells express cd25 (cd25+) a pan b cell marker such as b220 (b220+), and also express cd19 (cd19+).
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Methods of preparing anti-human papillomavirus antigen t cells

Disclosed are methods of preparing an isolated population of human papillomavirus (hpv)-specific t cells comprise dividing an hpv-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining t cells from the cultured multiple fragments; testing the t cells for specific autologous hpv-positive tumor recognition; selecting the t cells that exhibit specific autologous hpv-positive tumor recognition; and expanding the number of selected t cells to produce a population of hpv-specific t cells for adoptive cell therapy. Related methods of treating or preventing cancer using the t cells are also disclosed..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Compositions, kits and methods for treatment of cardiovascular,immunological and inflammatory diseases

Compositions, kits, cells and methods for treating cardiovascular (e.g., myocardial ischemia and heart failure), immunological, and inflammatory diseases or disorders involve the use of the mature and precursor sequences of micrornas 142-5p, 142-3p, 17-5p, 17-3p, 374, and 20a, and of antisense molecules complementary to these sequences, to manipulate processes relevant to, for example, the cardiac response to stress, including survival signaling, angiogenesis, stem cell differentiation along muscle or vascular lineages, and repression or promotion of cardiac myocyte growth. Also described are methods to treat cardiovascular, immunological and inflammatory diseases by engineering cells containing specific micro-rnas or antagomirs against specific mrnas.
University Of Miami

3d tissue-engineered bone marrow for personalized therapy and drug development

A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow.
Washington University

Method for producing autologous proteins

A method of introducing proteins to a patient is provided for treating a wide variety of diseases. The method includes collecting blood from a patient's vein.
Arthrogen Gmbh

Formulations containing and kit for using adipose-derived stem cells and use thereof

Methods and kits for producing cellular fractions enriched in adipose derived stem cells. Methods are provided where adipose tissue obtained from liposuction is enzymatically treated using a solution containing collagenase and divalent cations prior to the application of traditional methods of stromal-vascular fraction isolation.
Antria, Inc.

Method of processing a veterinary tumor vaccine and a veterinary tumor vaccine processing kit

The present invention provides methods for preparing and administering a tumor vaccine. The processes include resecting tumors and isolating tumor cells, followed by treatment with ultraviolet radiation to activate the tumor cells.

Extemporaneous preparation of autologous fibrin

An autologous fibrin is prepared extemporaneously from either a full blood sample or a prepared sample of poor platelet plasma wherein the latter is subjected to a dedicated treatment and combined isolation process performed by a removable single-use device wherein blood or plasma components are separated and subsequently treated individually to be eventually combined by the user outside the system. The the system includes a platform and a removable single-use device both being designed to cooperate mechanically..
Avance Medical SÀrl

Harvesting bone graft material for use in spinal and other bone fusion surgeries

A technique for harvesting bone graft material for spinal and other fusion surgeries. In the disclosed embodiment, a bone cutting blade is placed in a disc space between two vertebrae to be fused.

Methods and compositions for optimized expansion and implantation of mesenchymal stem cells

Compositions and methods are provided for the optimized expansion and implantation of mesenchymal stem cells into a patient in need thereof. autologous mesenchymal stem cells (mscs) to a patient in need of mscs are harvested, expanded within novel growth parameters under the influence of autologous growth factors located on the patient's platelets..

Wound healing via autologous stem cell mobilization

The present invention relates to the field of wound healing. More specifically, the present invention provides methods and compositions useful for improved wound healing via autologous stem cell mobilization.



Autologous topics:
  • Autologous
  • Stem Cells
  • Differentiation
  • Fibroblast
  • Cell Therapy
  • Transplant
  • Cell Differentiation
  • Tissue Engineering
  • Myeloid Leukemia
  • Gene Expression
  • Acute Myeloid Leukemia
  • Complication
  • Umbilical Cord
  • Premature Birth
  • Premature Infant


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Autologous for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autologous with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.4342

    file did exist - 2171

    2 - 1 - 47